Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × vatalanib × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 1 Primary Myelofibrosis 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Gliosarcoma 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

pembrolizumab 66 Nivolumab 50 Ipilimumab 38 Cyclophosphamide 29 aldesleukin 23 Interleukin-2 22 Temozolomide 17 fludarabine 15 Biopsy 11 trametinib 9 fludarabine phosphate 9 dabrafenib 9 Dacarbazine 8 sargramostim 7 Paclitaxel 7 Cisplatin 7 Bevacizumab 7 lenvatinib 6 cemiplimab 6 binimetinib 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 epacadostat 5 Vemurafenib 5 Specimen Handling 5 Radiotherapy 5 Magnetic Resonance Spectroscopy 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 toripalimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00615160 2021-10-06

PTK/ZK in Disseminated Malignant Melanoma

University Hospital Schleswig-Holstein

Phase 1/2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡